Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 8/20 | 0.46 |
| ▸ | JAK2 | O60674 | 6/20 | 0.43 |
| ▸ | HTR5A | P47898 | 1/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.42 |
| ▸ | JAK3 | P52333 | 1/20 | 0.41 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.40 |
| ▸ | CD38 | P28907 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18318006 | 0.88 | CSF1R (0.49) | CSF1RJAK2MAP4K4SLC2A1 | |
| SCHEMBL7496024 | 0.86 | DHODH (0.46) | LMNA | |
| SCHEMBL2718101 | 0.85 | TSHR (0.43) | CSF1RLMNA | |
| SCHEMBL9875438 | 0.84 | LMNA (0.56) | CSF1RPDE4BLMNASLC2A1 | |
| SCHEMBL2479384 | 0.82 | LMNA (0.42) | CSF1RPDE4BLMNASLC2A1CD38 | |
| SCHEMBL2725311 | 0.82 | HTT (0.49) | CSF1RPDE4BLMNASLC2A1 | |
| SCHEMBL4627675 | 0.81 | SLC2A1 (0.48) | CSF1RPDE4BLMNASLC2A1 | |
| SCHEMBL5929785 | 0.79 | NNMT (0.46) | CSF1RLMNASLC2A1 | |
| SCHEMBL4657732 | 0.78 | PDE4B (0.49) | PDE4B | |
| SCHEMBL3273151 | 0.78 | KDM4E (0.64) | CSF1RPDE4BLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1687276-B1 | NOVEL METHOD OF PREPARING 3-FLUORINATED QUINOLINES | NOVEXEL (FR) | 2009-10-14 | — | — | EP | disclosed |
| US-7396934-B2 | Process for preparing 3-fluoroquinolines | NOVEXEL (FR) | 2008-07-08 | — | — | US | disclosed |
| EP-1687276-A1 | NOVEL METHOD OF PREPARING 3-FLUORINATED QUINOLINES | NOVEXEL (FR) | 2006-08-09 | — | — | EP | disclosed |
| US-20050182259-A1 | Subjecting a substituted quinoline-3-carboxamide compound to Hofmann degradation to obtain amine derivative, forming diazonium salt by reacting amine derivative with borontrifluoride-ethyl ether complex, heating to form 3-fluoroquinolines; intermediate for forming antibacterial compound | AVENTIS PHARMA S.A. (US) | 2005-08-18 | — | — | US | disclosed |
| WO-2005049575-A1 | NOVEL METHOD OF PREPARING 3-FLUORINATED QUINOLINES | NOVEXEL (FR) | 2005-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050182259-A1 | Subjecting a substituted quinoline-3-carboxamide compound to Hofmann degradation to obtain amine derivative, forming diazonium salt by reacting amine derivative with borontrifluoride-ethyl ether complex, heating to form 3-fluoroquinolines; intermediate for forming antibacterial compound | QRFPR, NQO2, DHX35 | CSF1R 598/4885JAK2 3680/4885HTR5A 137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.